Apellis Pharmaceuticals, Inc.

APLS

$41.03

+0.00%

N/A+$0.00

Healthcare

Biotechnology

NASDAQ

Inactive

Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy ...

Key Metrics of APLS

Snapshot

Latest / TTM · 6 periods

Market Cap

$5.25B

ROCE

20.7%

EV / EBITDA

29.54x

+13.3% YoY

FCF Yield

0.7%

-0.7% YoY

Cash Conversion Cycle

422.4d

Current Ratio

3.63

Quick take

TTM —

Positive CCC

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$3.99B	$5.49B	$7.10B	$3.95B	$3.17B	$5.25B
Enterprise ValueCompany value including debt and cash adjustments.	$3.56B	$5.05B	$6.86B	$4.01B	$3.18B	$5.32B
EV / SalesHow many dollars investors pay per dollar of sales.	53.50x	66.93x	17.31x	5.13x	3.17x	4.81x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-4.87x	-8.18x	-13.86x	-25.96x	45.49x	29.54x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	0.59	0.71	0.49	-0.38	0.26	0.38

Returns + ROCE gauge

ROCE latest

20.7%

Prev year 7.4%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-375.7%	-383.9%	-271.8%	-86.6%	6.0%	39.7%
ROAProfit generated from total assets.	-84.6%	-85.8%	-67.0%	-22.4%	2.1%	12.3%
ROICReturn generated on invested operating capital.	-102.1%	-107.4%	-92.4%	-25.3%	8.9%	23.0%
ROCEOperating return on long-term capital used.	-71.5%	-100.3%	-95.6%	-23.6%	7.4%	20.7%
Earnings YieldEarnings as a percentage of market value.	-18.7%	-11.9%	-7.4%	-5.0%	0.7%	2.6%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-550.98M	$-482.61M	$-565.81M	$-47.64M	$86.18M	$80.77M
FCFECash flow available to equity holders after debt flows.	$-564.23M	$-515.27M	$-595.51M	$277.19M	$45.01M	$37.78M
FCF YieldFree cash flow divided by market capitalization.	-14.1%	-9.4%	-8.4%	-2.2%	1.4%	0.7%
Income QualityHow well accounting earnings are backed by cash flow.	0.75	0.79	1.13	0.44	2.02	0.34
Capex / OCFShare of operating cash flow spent on capital expenditures.	-0.2%	-0.3%	-0.1%	-0.5%	0.7%	0.0%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	439.2d	37.4d	190.0d	126.9d	133.2d	147.0d
DIOAverage days inventory stays before being sold.	1684.8d	5551.0d	913.0d	255.7d	508.9d	439.4d
DPOAverage days the company takes to pay suppliers.	1186.9d	2418.4d	234.0d	119.6d	202.8d	164.0d
Operating CycleTime from buying inventory to collecting receivables.	2124.1d	5588.4d	1103.0d	382.7d	642.1d	586.4d
Cash Conversion CycleNet days cash is tied in operations.	937.2d	3170.1d	869.0d	263.1d	439.3d	422.4d

Snapshot

Latest / TTM: —

Market Cap

$5.25B

ROE

39.7%

FCF Yield

0.7%

Current Ratio

3.63

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer